KRW 23100.0
(-0.86%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 2.61 Billion KRW | 36.26% |
2022 | 1.92 Billion KRW | -77.31% |
2021 | 8.47 Billion KRW | -38.28% |
2020 | 13.72 Billion KRW | 7.12% |
2019 | 12.81 Billion KRW | -57.27% |
2018 | 29.99 Billion KRW | 533.33% |
2017 | 4.73 Billion KRW | 0.0% |
2016 | - KRW | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 2.14 Billion KRW | 0.0% |
2024 Q1 | 2.64 Billion KRW | -100.0% |
2023 FY | 2.61 Billion KRW | 36.26% |
2023 Q2 | 1.87 Billion KRW | -2.7% |
2023 Q3 | 2.09 Billion KRW | 11.95% |
2023 Q4 | 2.61 Billion KRW | 24.81% |
2023 Q1 | 1.92 Billion KRW | 0.23% |
2022 Q2 | - KRW | -100.0% |
2022 FY | 1.92 Billion KRW | -77.31% |
2022 Q4 | 1.92 Billion KRW | -16.2% |
2022 Q3 | 2.29 Billion KRW | 0.0% |
2022 Q1 | 8.62 Billion KRW | 1.77% |
2021 Q3 | 14.46 Billion KRW | 0.0% |
2021 FY | 8.47 Billion KRW | -38.28% |
2021 Q4 | 8.47 Billion KRW | -41.42% |
2020 FY | 13.72 Billion KRW | 7.12% |
2019 FY | 12.81 Billion KRW | -57.27% |
2018 FY | 29.99 Billion KRW | 533.33% |
2017 FY | 4.73 Billion KRW | 0.0% |
2016 FY | - KRW | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
HLB Pharmaceutical Co., Ltd | 988.75 Million KRW | -164.959% |
CMG Pharmaceutical Co., Ltd. | 19.06 Billion KRW | 86.258% |
Celltrion Pharm, Inc. | 4.33 Billion KRW | 39.543% |
Huons Global Co., Ltd. | 66.94 Billion KRW | 96.087% |
DongKook Pharmaceutical Co., Ltd. | 18.74 Billion KRW | 86.028% |
Enzychem Lifesciences Corporation | 1.02 Billion KRW | -155.59% |
Humedix Co., Ltd. | 1.75 Billion KRW | -49.248% |
Boditech Med Inc. | 2.09 Billion KRW | -24.756% |
EuBiologics Co., Ltd. | 2.8 Billion KRW | 6.436% |
Huons Co., Ltd. | 58.35 Billion KRW | 95.51% |
BNC Korea Co., Ltd. | 301.69 Million KRW | -768.373% |
AptaBio Therapeutics Inc. | 13.56 Billion KRW | 80.693% |